Aptevo Therapeutics

Aptevo Therapeutics Inc. announced agreements for the exercise of warrants to purchase 823,544 shares at $7.50 each, expected to yield $6.2M. New unregistered warrants for 1,647,088 shares at $9.53 each will be issued. Proceeds will be used for working capital and general corporate purposes. The offering is expected to close on December 13, 2024.

100% of patients in Cohort 1 of Aptevo’s RAINIER AML trial achieved remission within 30 days, including two with MRD-negative status. Cohort 2 enrollment is commencing.

Aptevo Therapeutics announced 100% remission in Cohort 1 of its RAINIER AML Phase 1b trial within 30 days, with two out of three patients achieving MRD-negative status. Mipletamig, in combination with venetoclax and azacitidine, showed consistent success, with 86% remission across trials. Cohort 2 enrollment has begun.

Aptevo Therapeutics and Alligator Bioscience report positive Phase 1 trial data for ALG.APV-527, a bispecific antibody for solid tumors, meeting key endpoints for safety, tolerability, and biological activity. 56% of evaluable patients achieved stable disease, with no serious liver toxicity observed.

The hemophilia drugs market focuses on treatments for hemophilia A and B, including factor replacement, gene therapy, and bypassing agents. Key drivers are the increasing prevalence of hemophilia, advances in biotechnology, and heightened awareness of early diagnosis. Major companies include Grifols SA, CSL Behring, and Pfizer, Inc. The market is segmented by treatment type, product, route of administration, and geography, with North America and Europe leading due to advanced healthcare infrastructure and supportive regulatory frameworks. Asia-Pacific is expected to see rapid growth due to improving healthcare facilities and increasing awareness.

StockNews.com initiated coverage on Aptevo Therapeutics (NASDAQ:APVO) with a 'sell' rating. Roth Mkm lowered their target price to $8.00 and maintained a 'buy' rating. Aptevo Therapeutics' stock remained flat at $0.17, with a 50-day SMA of $0.32 and a 200-day SMA of $0.92. Armistice Capital LLC acquired a new stake, owning 18.36% of the company.